Evaluation of Serum Mammaglobin as an Alternative Biomarker in the Diagnosis of Breast Tumors
Open Access
- 17 August 2022
- journal article
- research article
- Published by Scientific Scholar in Journal of Laboratory Physicians
- Vol. 15 (01) , 020-024
Abstract
Introduction Breast cancer is the most common cancer in women in India and accounts for 14% of all cancers in women. Rise in mortality is due to lack of awareness and proper screening. Mammography and presently available serum biomarkers have low sensitivity and specificity. In our quest to identify a better biomarker, we studied mammaglobin (MAM) in patients with breast cancer and benign breast tumors. Aim To evaluate serum mammaglobin in breast cancer patients and compare it with benign breast tumor patients and healthy controls. To compare it with existing biomarkers serum carcinoembryonic antigen (CEA) and cancer antigen 15–3 (CA 15–3). Materials and methods: This is a cross-sectional, case–control study of 77 subjects, of which 27 were breast cancer patients, 20 benign breast tumor patients, and 30 healthy controls. Serum CEA and CA15–3 were estimated by electrochemiluminescence immunoassay (ECLIA) and mammaglobin (MAM) by enzyme-linked immunosorbent assay (ELISA). Results Mammaglobin and CEA levels were elevated in breast cancer patients, followed by benign breast tumors when compared with controls (P < 0.000001). Mammaglobin showed 81.5% sensitivity, 100% specificity, 100% positive predictive value (PPV), and 88.9% negative predictive value (NPV). CEA showed 88.9% sensitivity, 82.5% specificity, 77.4% PPV, and 91.7% NPV. The area under the curve was the highest for MAM (0.892), followed by CEA (0.889) and CA 15–3 (0.555). CA15–3 showed poor diagnostic efficacy. Combined receiver operating characteristic (ROC) curve of the biomarkers MAM and CEA had an AUC of 0.913. Conclusion Mammaglobin proved to be an efficacious biomarker in diagnosing breast cancer.Keywords
This publication has 12 references indexed in Scilit:
- Diagnostic and prognostic value of carcinoembryonic antigen in pancreatic cancer: a systematic review and meta-analysisOncoTargets and Therapy, 2017
- Epidemiology of breast cancer in Indian womenAsia-Pacific Journal of Clinical Oncology, 2017
- Tumor marker CA 15-3 in breast cancer patientsActa Medica Academica, 2015
- Human mammaglobin in breast cancer: a brief review of its clinical utility2014
- Mammaglobin peptide as a novel biomarker for breast cancer detectionCancer Biology & Therapy, 2013
- Expression of human mammaglobin and clinicopathologic correlations in breast cancer: The findings in MalaysiaIndian Journal of Pathology and Microbiology, 2011
- Mammaglobin as a potential molecular target for breast cancer drug deliveryCancer Cell International, 2009
- Identification of Mammaglobin as a Novel Serum Marker for Breast CancerClinical Cancer Research, 2005
- Mammaglobin as a Novel Breast Cancer Biomarker: Multigene Reverse Transcription-PCR Assay and Sandwich ELISAClinical Chemistry, 2004
- A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study.2001